Pfizer reports FDA approval for wider use of Aromasin

10/6/2005 | Bloomberg Businessweek

The FDA has expanded approval of the breast cancer drug to include post-surgery therapy for patients with early breast cancer, Pfizer said. The tablets have been approved since 1999 for treating advanced breast cancer after standard chemotherapy, and a study showed women who switched to Aromasin after two to three years of tamoxifen were more likely to avoid a cancer recurrence than those who continued with tamoxifen.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX